BNTX Share Price Performance
US$83.89
-14.50 (-14.74%)
39.9% undervalued intrinsic discount
US$139.51
Fair Value
Price US$83.89
AnalystConsensusTarget US$139.51
AnalystLowTarget US$104.35
Hansimglueck US$499.94
Fair ValueUS$139.51
Share Pricen/a
BioNTech SE Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 84 Fair Values set on narratives written by author
BNTX Community Narratives
AN
Fair Value US$139.51 39.9% undervalued intrinsic discount
Oncology Pipeline Expansion And Vaccine Policy Shifts Will Shape Future Performance
3users have liked this narrative
0users have commented on this narrative
66users have followed this narrative
AN
Fair Value US$104.35 19.6% undervalued intrinsic discount
Falling Vaccine Demand And Looming Regulatory Risks Will Crush Value
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
HA
Fair Value US$499.94 83.2% undervalued intrinsic discount
Game Changer in Cancer Treatment
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Game Changer in Cancer Treatment
"Amputation, intoxication and radiation". If students read about our current cancer treatment in 2050, they would probably date it back to 1960-70.Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
HA
US$499.94
83.2% undervalued intrinsic discount
Hansimglueck's Fair Value
Profit Margin
18.58%
Future PE
28.98x
Price in 2031
US$727.21
Falling Vaccine Demand And Looming Regulatory Risks Will Crush Value
Key Takeaways Decreasing vaccine demand, stricter regulations, and patent expirations threaten long-term revenue and profitability across BioNTech's main franchises. High R&D spending on oncology and strong competition could increase costs, reduce pricing power, and limit future earnings growth.Read more
29
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$104.35
19.6% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
10.89%
Future PE
137.55x
Price in 2029
US$127.12
Oncology Pipeline Expansion And Vaccine Policy Shifts Will Shape Future Performance
Key Takeaways Expanding oncology pipeline, innovative mRNA technologies, and global partnerships position BioNTech for long-term growth and improved profitability through revenue diversification. Increased investment in R&D and manufacturing capacity enables broader market penetration and reduces dependence on COVID-19 vaccine sales.Read more
651
users have viewed this narrative3users have liked this narrative
0users have commented on this narrative
66users have followed this narrative
AN
US$139.51
39.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
15.7%
Future PE
79.08x
Price in 2029
US$169.85
Advanced mRNA And Oncology Programs Will Unlock Global Healthcare Demand
Key Takeaways BioNTech's innovative mRNA pipeline, AI integration, and global partnerships position it for leadership in oncology and vaccine markets with sustained revenue and margin growth. Strategic M&A, diversified manufacturing, and strong financials provide resilience, flexibility, and recurring revenues amid rising global health spending and biodefense investment.Read more
82
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$174.1
51.8% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
8.15%
Future PE
146.94x
Price in 2028
US$210.67
Trending Discussion
Recently Updated Narratives
HA
Game Changer in Cancer Treatment
Fair Value: US$499.94 83.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BNTX: Oncology Pipeline Progress And Mixed Rating Shifts Will Shape Expectations
Fair Value: US$104.35 19.6% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BNTX: Oncology Pipeline Progress Will Drive Future Upside Despite Recent Downgrades
Fair Value: US$139.51 39.9% undervalued intrinsic discount
66 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioNTech SE Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 05, 2026
- -4.53
- 77.64%
- -39.59%
- 1.4%
About BNTX
- Founded
- 2008
- Employees
- 6772
- CEO
- WebsiteView website
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
